Judy Mwangi

Clinical targeting of HIV capsid protein with a long-acting small molecule

John O. Link, Martin S. Rhee, Winston C. Tse et al. · Nature · 2020 · 421 citations · Full text

Pharmacy, Molecular Biology, Pharmaceutics +12

Preclinical Characterization of GS-9669, a Thumb Site II Inhibitor of the Hepatitis C Virus NS5B Polymerase

Martijn Fenaux, Stacey Eng, Stephanie A. Leavitt et al. · Antimicrobial Agents and Chemotherapy · 2012 · 42 citations · Full text

Life Sciences, Infectious Diseases, Medicinal Chemistry +17

Discovery of GS-9669, a Thumb Site II Non-Nucleoside Inhibitor of NS5B for the Treatment of Genotype 1 Chronic Hepatitis C Infection

Scott E. Lazerwith, Willard Lew, Jennifer Zhang et al. · Journal of Medicinal Chemistry · 2013 · 37 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Long-acting capsid inhibitor protects macaques from repeat SHIV challenges

Samuel J. Vidal, Elena Bekerman, Derek Hansen et al. · Nature · 2021 · 27 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacokinetics +17

539. GS-CA2: A Novel, Potent, and Selective First-In-class Inhibitor of HIV-1 Capsid Function Displays Nonclinical Pharmacokinetics Supporting Long-Acting Potential in Humans

Jim Zheng, Stephen R. Yant, Shekeba Ahmadyar et al. · Open Forum Infectious Diseases · 2018 · 14 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17